The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin

Cancer Research

Volumn 63, Issue 2, 2003, Pages 382-385

  Dings, Ruud P M ^a   Yokoyama, Yumi ^b   Ramakrishnan, Sundaram ^b   Griffioen, Arjan W ^c   Mayo, Kevin H ^a  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINEX; ANGIOSTATIN; CARBOPLATIN; PEPTIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL DIVISION; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PLASMINOGEN; PROTEINS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037439824     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
2. Williams, S. G., Buscarini, M., and Stein, J. P. Molecular markers for diagnosis, staging, and prognosis of bladder cancer. Oncology (Basel), 15: 1469-1470, 1473-1474, 1476-1484. 2001.
3. Weidner, N. Angiogenesis as a predictor of clinical outcome in cancer patients. Hum. Pathol., 31: 403-405, 2000.
4. Gorski, D. H., Mauceri, H. J., Salloum, R. M., Gately, S., Hellman, S., Beckett, M. A., Sukhatme, V. P., Soff, G. A., Kufe, D. W., and Weichselbaum, R. R. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res., 58: 5686-5689, 1998.
5. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394: 287-291, 1998.
6. Wilczynska, U., Kucharska, A., Szary, J., and Szala, S. Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer. Acta Biochim. Pol., 48: 1077-1084, 2001.
7. Teicher, B. A., Sotomayor, E. A., and Huang, Z. D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res., 52: 6702-6704, 1992.
8. Griffioen, A. W., van der Schaft, D. W., Barendsz-Janson, A. F., Cox, A., Struijker Boudier, H. A., Hillen, H. F., and Mayo, K. H. Anginex, a designed peptide that inhibits angiogenesis. Biochem. J., 354: 233-242, 2001.
9. Yokoyama, Y., Dhanabal, M., Griffioen, A. W., Sukhatme, V. P., and Ramakrishnan, S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res., 60: 2190-2196, 2000.
10. Dhanabal, M., Ramchandran, R., Volk, R., Stillman, I. E., Lombardo, M., Iruela-Arispe, M. L., Simons, M., and Sukhatme, V. P. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res., 59: 189-197, 1999.
11. Mohanraj, D., Olson, T., and Ramakrishnan, S. Expression of biologically active human vascular endothelial growth factor in yeast. Growth Factors, 12: 17-27, 1995.
12. Wild, R., Ramakrishnan, S., Sedgewick, J., and Griffioen, A. W. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc. Res., 59: 368-376, 2000.
13. Alvarez, A. A., Krigman, H. R., Whitaker, R. S., Dodge, R. K., and Rodriguez, G. C. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res., 5: 587-591, 1999.
14. Harries, M., and Kaye, S. B. Recent advances in the treatment of epithelial ovarian cancer. Expert Opin. Investig. Drugs. 10: 1715-1724, 2001.
15. Tattersall, M. H. N. Ovarian cancer chemotherapy: carboplatin as standard. Lancet, 360: 500-501, 2002.
16. ICON. Paclitaxel plus carboplatin versus standard chemotherapy with either singleagent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 360: 505-515, 2002.